A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | MicrobiomeTrials
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-07-23Est. Completion: 2028-05-30
Enrollment target: 392 participants
Locations
City of Hope Phoenix Cancer Center, Goodyear, Arizona, United States
City of Hope National Medical Center, Duarte, California, United States
City of Hope Chicago Cancer Center, Zion, Illinois, United States
Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania, United States
Scri Oncology Partners, Nashville, Tennessee, United States
The University of Texas Md Anderson Cancer Center, Houston, Texas, United States
Centro Gaucho Integrado de Oncologia Hospital Mae de Deus, Porto Alegre, Brazil
Hospital Da Bahia, Salvador, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto, Brazil
Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, São Paulo, Brazil
Anhui Provincial Hospital, Hefei, Anhui, China
Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Other microbiome trials you might be interested in